# **Screening Libraries**

# **Product** Data Sheet

# Clascoterone

Cat. No.: HY-13331 CAS No.: 19608-29-8 Molecular Formula:  $C_{24}H_{34}O_{5}$ Molecular Weight: 402.52

Target: Androgen Receptor

Pathway: Vitamin D Related/Nuclear Receptor

Storage: Powder

> 4°C 2 years

3 years

In solvent -80°C 2 years

-20°C

-20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 100 mg/mL (248.43 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4843 mL	12.4217 mL	24.8435 mL
	5 mM	0.4969 mL	2.4843 mL	4.9687 mL
	10 mM	0.2484 mL	1.2422 mL	2.4843 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.75 mg/mL (6.83 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (6.83 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.75 mg/mL (6.83 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	Clascoterone (Cortexolone 17 alpha-propionate; Cortexolone 17 $\alpha$ -propionate; CB-03-01) is a new topical and peripherally selective androgen antagonist.
IC <sub>50</sub> & Target	Androgen Receptor <sup>[1]</sup> .
In Vivo	Clascoterone is a new potent topical antiandrogen potentially useful in acne vulgaris. Clascoterone 1% cream was very well

tolerated, and was significantly better than placebo regarding TLC (P = 0.0017), ILC (P = 0.0134) and ASI (P = 0.0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Trifu V, et al. Cortexolone  $17\alpha$ -propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011 Jul;165(1):177-83.

[2]. Celasco G, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-6.

[3]. Trifu V, et al. Cortexolone 17\, propionate 1\% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0\, 005\% cream. Br J Dermatol. 2011 Jul;165(1):177-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com